Tenaxis Medical, a developer of sealants that close surgical incisions, has raised $9.6 million of an expected $16.6 million in equity, according to a filing with the SEC. The company’s ArterX Vascular Sealant can achieve hemostasis, or cause bleeding to stop, in 15 seconds after it is applied to a suture line. Tenaxis is currently working on a new sealant for the gastrointestinal tract as well.
The company was founded in 2004 and is based in Mountain View, Calif.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more